SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-21-033346
Filing Date
2021-06-21
Accepted
2021-06-21 17:00:30
Documents
3
Period of Report
2021-06-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea142958-8k_aditxtherap.htm 8-K 24261
2 PRESS RELEASE, DATED JUNE 17, 2021 ea142958ex99-1_aditx.htm EX-99.1 9278
3 LEAD INDEPENDENT DIRECTOR CHARTER ea142958ex99-2_aditx.htm EX-99.2 22358
  Complete submission text file 0001213900-21-033346.txt   57266
Mailing Address 2569 WYANDOTTE, ST. SUITE 101 MOUNTAIN CA 94043
Business Address 2569 WYANDOTTE, ST. SUITE 101 MOUNTAIN CA 94043 909-488-0844
Aditx Therapeutics, Inc. (Filer) CIK: 0001726711 (see all company filings)

IRS No.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39336 | Film No.: 211031562
SIC: 2834 Pharmaceutical Preparations